177 related articles for article (PubMed ID: 18641023)
21. Primary (AL) amyloidosis with gastrointestinal involvement.
Madsen LG; Gimsing P; Schiødt FV
Scand J Gastroenterol; 2009; 44(6):708-11. PubMed ID: 19242859
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex.
Penot A; Abraham J; Debarri H; Desport E; Aguilar C; Lavergne D; Auroy F; Leleu X; Goldstein A; Kolb B; Bridoux F; Fermand JP; Leblond V; Jaccard A
Amyloid; 2011 Jun; 18 Suppl 1():145-7. PubMed ID: 21838466
[No Abstract] [Full Text] [Related]
23. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
Kyle RA; Greipp PR; Garton JP; Gertz MA
Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
[TBL] [Abstract][Full Text] [Related]
24. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
[TBL] [Abstract][Full Text] [Related]
25. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of primary AL amyloidosis and POEMS syndrome: efficacy of melphalan-dexamethasone and role of biochemical markers in monitoring the diseases course.
Adami F; Briani C; Binotto G; Altinier S; Tarantini G; Semenzato G
Am J Hematol; 2010 Feb; 85(2):131-2. PubMed ID: 20029992
[No Abstract] [Full Text] [Related]
27. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
[TBL] [Abstract][Full Text] [Related]
28. [Low-dose melphalan therapy for patients with intermediate- to high-risk myelodysplastic syndromes].
Liu L; Qin TJ; Xu ZF; Zhou CL; Zhang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):443-5. PubMed ID: 19954594
[TBL] [Abstract][Full Text] [Related]
29. Amyloidosis of immunoglobulin origin: useful treatment?
Brown MP; Walls RS
Med J Aust; 1990 Jan; 152(2):95-7. PubMed ID: 2104951
[TBL] [Abstract][Full Text] [Related]
30. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Kumar S; Dispenzieri A; Gertz MA
N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18172183
[No Abstract] [Full Text] [Related]
31. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900
[TBL] [Abstract][Full Text] [Related]
32. Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.
Buxbaum JN; Hurley ME; Chuba J; Spiro T
Am J Med; 1979 Nov; 67(5):867-78. PubMed ID: 116546
[No Abstract] [Full Text] [Related]
33. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
34. Renal amyloidosis: pathogenesis and therapy.
Jones NF
Clin Nephrol; 1976 Nov; 6(5):459-64. PubMed ID: 136327
[No Abstract] [Full Text] [Related]
35. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lachmann HJ; Wechalekar AD; Gillmore JD
N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
[No Abstract] [Full Text] [Related]
36. Myelodysplasia in the Wellington region 2002-2007: disease incidence and treatment patterns.
Irwin J; D'Souza A; Johnson L; Carter J
Intern Med J; 2011 May; 41(5):399-407. PubMed ID: 21299783
[TBL] [Abstract][Full Text] [Related]
37. A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.
Christou L; Hatzimichael EC; Sotsiou-Candila F; Siamopoulos K; Bourantas KL
Acta Haematol; 1999; 101(4):202-5. PubMed ID: 10436302
[TBL] [Abstract][Full Text] [Related]
38. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
Palladini G; Russo P; Lavatelli F; Nuvolone M; Albertini R; Bosoni T; Perfetti V; Obici L; Perlini S; Moratti R; Merlini G
Ann Hematol; 2009 Apr; 88(4):347-50. PubMed ID: 18779964
[TBL] [Abstract][Full Text] [Related]
39. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lokhorst HM; Hazenberg BP; Croockewit A
N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18172953
[No Abstract] [Full Text] [Related]
40. [Systemic ALlambda amyloidosis associated with vascular fragility].
Laimer M; Kaindl K; Emberger M; Hawranek T; Lanschützer CM; Bauer JW; Linke RP; Mlineritsch B; Hintner H
J Dtsch Dermatol Ges; 2004 Nov; 2(11):934-9. PubMed ID: 16281613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
